Remi Barbier, Cassava CEO
September 3, 2021 09:32 AM EDTUpdated 09:45 AM
R&D

Cas­sa­va CEO goes on the of­fen­sive over da­ta al­le­ga­tions, shout­ing down 'short at­tack'

Kyle Blankenship

Alzheimer’s play­er Cas­sa­va Sci­ences has been un­der fire in re­cent days af­ter a cit­i­zen pe­ti­tion with the FDA sug­gest­ed the com­pa­ny was play­ing fast and …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

A service from the Financial Times